A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

NCT05971940 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety and effects of the medication Orforglipron (LY3502970) in adults with type 2 diabetes who do not have adequate blood sugar control through diet and exercise alone.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 559 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-08 · est. completion 2025-04

Where 89 sites · China, India, Japan, Mexico, Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT05971940 ↗

Description as written by the study sponsor.

The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The study will last approximately 54 weeks.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally
Placebo Drug

Administered orally

Main thing measured	Change From Baseline in HbA1c
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05971940 ↗